Business Context and Reporting Period
Company: OncoGenex Pharmaceuticals, Inc. (Note: Metadata lists "ACHIEVE LIFE SCIENCES, INC." but the filing text identifies OncoGenex Pharmaceuticals, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: April 24, 2015
Event: Termination of a Material Definitive Agreement with Teva Pharmaceutical Industries Ltd. regarding the investigational compound custirsen.
Key Financial Metrics
This filing does not report standard periodic financial metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial impact disclosed is a one-time payment related to the termination of a collaboration agreement.
- Termination Payment: Teva agreed to pay the Company approximately $23.2 million ($27 million less a $3.8 million reduction).
- Hold-Back Amount: $3 million of the reduction is a hold-back subject to future deductions for costs incurred after January 1, 2015.
- Payment Schedule: The remaining hold-back amount will be paid in three installments: 50% at six months, 50% at nine months, and the balance at 12 months post-closing.
- Expense Responsibility: Teva is responsible for custirsen expenses through December 31, 2014. The Company assumes responsibility for expenses from January 1, 2015, forward.
Material Changes Versus Prior Period
The filing details a material change in the Company's operational and intellectual property landscape regarding custirsen:
- Agreement Termination: The Collaboration and License Agreement dated December 20, 2009, was terminated effective April 24, 2015.
- Intellectual Property Transfer: Teva assigned certain patent applications to the Company and granted an exclusive license (except to Teva) for know-how created during the collaboration. Teva also granted a non-exclusive license to its own IP for custirsen development.
- Study Sponsorship: Sponsorship of the ENSPIRIT Phase 3 study and the investigational new drug application (IND) for custirsen was transferred from Teva to the Company.
- Liability Release: Both parties released each other from claims related to the Collaboration Agreement, with specific indemnity obligations defined for periods before and after the agreement.
Guidance, Outlook, and Risks
Management Commentary: The Company has regained full control over the development and commercialization of custirsen and certain other antisense inhibitors of clusterin. The Company will submit amendments to the ENSPIRIT study protocol as it becomes the sponsor in applicable countries.
Risks and Contingencies:
- Study Termination: If the Company elects to terminate the ENSPIRIT study, Teva's consent is required prior to the Company becoming the sponsor in all jurisdictions. However, if a drug monitoring safety committee recommends termination for safety or futility, the Company may terminate the study in jurisdictions where it is the sponsor.
- Third-Party Agreements: If additional historical third-party agreements are discovered post-closing, Teva is responsible for costs exceeding $100,000, while the Company is responsible for the initial $100,000.
- Patent Restrictions: Teva agreed not to challenge the Company's patents or file new patent applications covering custirsen for 18 months post-closing.
Investor Verification Checklist
- Verify the exact net cash receipt amount after the $3.8 million reduction and any subsequent deductions from the $3 million hold-back.
- Confirm the timeline for the transfer of IND sponsorship and the submission of protocol amendments for the ENSPIRIT study across different jurisdictions.
- Review the specific terms of the indemnity agreements regarding third-party claims for the AFFINITY study and pre-agreement development.
- Assess the Company's financial capacity to fund custirsen development expenses starting January 1, 2015, without Teva's support.
- Monitor the status of the $3 million hold-back payments scheduled for 6, 9, and 12 months post-closing.